Literature DB >> 1716098

FK-506 and cyclosporin A: selective inhibition of calcium ionophore-induced polymorphonuclear leukocyte degranulation.

M J Forrest1, M E Jewell, G C Koo, N H Sigal.   

Abstract

This paper investigates the abilities of FK-506 and cyclosporin A (CsA) to inhibit human polymorphonuclear leukocyte (PMNL) degranulation. PMNLs, purified from human blood, were stimulated in vitro with A23187, ionomycin, the complement derived peptide C5a, formylmethionylleucinylphenylalanine (FMLP) or phorbol myristate acetate (PMA). Degranulation was assessed by measuring the release of either lactoferrin or N-acetyl-beta-D-glucosaminidase (NAG). Both FK-506 and CsA produced a concentration-related inhibition of degranulation induced by either A23187 or ionomycin but did not affect C5a-, FMLP- or PMA-induced degranulation. The IC50 values for inhibition of degranulation (approximately 0.7 nM for FK-506 and 33.7 nM for CsA) are very close to the published values for inhibition of human T-cell proliferation. Removal of calcium from the incubation medium with ethyleneglycolbis(aminoethylether)tetra-acetate (EGTA) totally inhibited calcium ionophore-induced degranulation but had no effect against C5a-, FMLP- or PMA-induced degranulation. Preincubation of PMNLs with actinomycin D or cycloheximide did not affect either A23187- or PMA-induced degranulation. Non-immunosuppressive analogs of CsA were ineffective at inhibiting degranulation. Rapamycin, a macrolide structurally related to FK-506, did not inhibit degranulation but it did antagonize the inhibition produced by FK-506. Given the similar profiles of activity of FK-506 and CsA in neutrophils and T cells, we conclude that similar activation or signal transduction pathways may be present in both T cells and neutrophils. Because A23187-induced PMNL degranulation was not sensitive to either actinomycin D or cycloheximide, it is apparent that the signal transduction pathways ultimately control different cellular functions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716098     DOI: 10.1016/0006-2952(91)90257-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Effects of FK506 and cyclosporin A on proliferation, histamine release and phenotype of murine mast cells.

Authors:  N Toyota; Y Hashimoto; S Matsuo; Y Kitamura; H Iizuka
Journal:  Arch Dermatol Res       Date:  1996-07       Impact factor: 3.017

2.  Effects of cyclosporin A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12.

Authors:  R E Kaye; D A Fruman; B E Bierer; M W Albers; L D Zydowsky; S I Ho; Y J Jin; M C Castells; S L Schreiber; C T Walsh
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

3.  The effect of the immunophilin ligands rapamycin and FK506 on proliferation of mast cells and other hematopoietic cell lines.

Authors:  T Hultsch; R Martin; R J Hohman
Journal:  Mol Biol Cell       Date:  1992-09       Impact factor: 4.138

4.  Partial inhibition of human neutrophil activation by FK-506 at supratherapeutic concentrations.

Authors:  K Wenzel-Seifert; R Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

Review 5.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Authors:  D H Peters; A Fitton; G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

6.  Cyclosporin A (CsA) modulates the glomerular production of inflammatory mediators and proteoglycans in experimental nephrosis.

Authors:  C Bustos; S González-Cuadrado; M Ruiz-Ortega; C Gómez-Guerrero; E González; J J Plaza; J Egido
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

Review 7.  Immunosuppression Affects Neutrophil Functions: Does Calcineurin-NFAT Signaling Matter?

Authors:  Ondřej Vymazal; Kamila Bendíčková; Marco De Zuani; Marcela Vlková; Marcela Hortová-Kohoutková; Jan Frič
Journal:  Front Immunol       Date:  2021-11-02       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.